Tranexamic acid dosage regimens on blood loss in Hemi-Mandibulectomy

The effect of different dosage regimens of Tranexamic acid on blood loss in Hemi-Mandibulectomy: A randomized double blind study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202110492542153

Enrollment

Registered

2021-10-20

Start date

2019-01-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health

Interventions

TRANEXAMIC ACID A

TRANEXAMIC ACID B

NORMAL SALINE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Willing and consenting patients aged 18-64years, 2. Healthy and physical status I and II according to the American Society of Anaesthesiologists (ASA) physical status classification

Exclusion criteria

Exclusion criteria: 1. Patients who refused to participate 2. Patients with known allergy to tranexamic acid 3. Patients with history or risk of thromboembolism (including patients on oral contraceptive pills, and anticoagulants)’ 4. Patients with uncontrolled hypertension, renal or hepatic dysfunction and coagulopathy, 5. Patients with likelihood of difficult intubation (Mallampati III and IV) were excluded from the study 6. Patients with haematological diseases or any form of bleeding diathesis following the review of the clotting profile including platelet count less than 150000/m3 7. Patients with a history of convulsion

Design outcomes

Primary

Measure	Time frame
Amount of Blood loss in millilitres	—

Secondary

Measure	Time frame
Units of Blood transfused in pints;Duration of operation in minutes	—

Countries

Nigeria

Contacts

Public ContactNdidi Okoro

Senior registrar

drokorondidi@gmail.com+2348036019521

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026